EDGAR·FLOW

Faeth Therapeutics, Inc. — Form 8-K

Filed November 9, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 78/100
What the filing says
Faeth announced positive Phase 2 topline results (as of October 30, 2026) for PIKTOR (serabelisib + sapanisertib) combined with paclitaxel in advanced endometrial cancer: 33% confirmed ORR (12 of 36 efficacy-evaluable patients) and 44% ORR in PIK3CA-mutant patients (7 of 16); median PFS 7.4 months with 62% 6-month PFS rate; safety profile acceptable with 12% hyperglycemia and 21% stomatitis (mostly low-grade). Company plans Phase 3 advancement pending regulatory alignment. Trial conducted with GOG Foundation across 42 treated patients with a median 2 prior therapy lines.
Why this rating

Clinical data validates lead asset and justifies Phase 3 progression; meaningful for $7.1M market-cap biotech dependent on single program success and future capital raises.

Tradability signal
NO TRADE

No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$18.10 ▲ 22.74%
at our read · unknown
$14.74
+10 min · unknown
$12.02 ▼ 18.48%
+30 min · unknown
$12.04 ▼ 18.31%
+1 hr · unknown
$11.27 ▼ 23.57%
+4 hrs · unknown
$12.29 ▼ 16.68%

The stock had already moved -18.52% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ FTH · stock on Yahoo Finance ↗

See more from November 9, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.